ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate | 40155-54-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate
• 英文别名: 4-(4-bromophenyl)-2,4-dioxobutyric acid ethyl ester
• CAS: 40155-54-2
• 化学式: C₁₂H₁₁BrO₄
• mdl: MFCD03411525
• 分子量: 299.121
• InChiKey: YAXZGVSOAFLCQS-UHFFFAOYSA-N

物化性质

• 沸点：
  410.4±30.0 °C(Predicted)
• 密度：
  1.467±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2918300090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate
CAS number: 40155-54-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H11BrO4
Molecular weight: 299.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate 在 盐酸羟胺 、 sodium methylate 、 potassium hydroxide 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 5-(4-溴苯基)异噁唑-3-羧酸
  参考文献：
  名称：

  新型吲哚-异恶唑杂化物：合成和体外抗胆碱酯酶活性

  摘要：

  背景：这项工作报告新型吲哚-异恶唑杂种的合成和体外胆碱酯酶抑制活性。 方法：从不同的5-芳基异恶唑-3-羧酸乙酯衍生物开始合成工艺。后面的化合物与色胺的水解和反应得到所需产物，收率高。 结论：在合成的化合物中，N-（2-（1H-吲哚-3-基）乙基）-5-（2-氯苯基）异恶唑-3-羧酰胺（4b）具有最佳的抗胆碱酯酶活性。

  DOI：

  10.2174/1570180813666161018124726
• 作为产物：
  描述：

  Ethyl 3-(4-bromophenyl)-4,5-dihydro-1,2-oxazole-5-carboxylate 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 以59%的产率得到ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate
  参考文献：
  名称：

  [2 + 2 + 1] N-甲苯磺酰腙、亚硝酸叔丁酯和烯烃的环加成：异恶唑啉的一般实用方法

  摘要：

  在过去的几十年里， N-甲苯磺酰腙已被证明是多功能的合成子。然而，据我们所知，基于N-甲苯磺酰腙的异恶唑啉的构建尚未得到研究。在此，我们报告了[2 + 2 + 1]环加成反应的首次演示，该反应可以使用N-甲苯磺酰腙、亚硝酸叔丁酯（TBN）和烯烃作为反应物轻松合成异恶唑啉。该过程代表了一种新型的环加成反应，具有独特的机制，不涉及氧化腈的参与。这种方法既通用又实用，具有广泛的底物范围、几乎通用的官能团兼容性、对水分和空气的耐受性、复杂生物活性分子功能化的潜力，并且易于扩大规模。对照实验和理论计算都表明，这种转化是通过N-甲苯磺酰腙和 TBN 的偶联原位生成硝基化合物，然后与烯烃进行环加成，然后消除叔丁氧基，得到所需的异恶唑啉。

  DOI：

  10.1039/d1sc02352g

文献信息

• [EN] LIVER X RECEPTOR (LXR) MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR X DU FOIE
  申请人：ALEXAR THERAPEUTICS INC

  公开号：WO2015035015A1

  公开（公告）日：2015-03-12

  Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

  本文描述了肝X受体（LXR）调节剂以及在治疗与LXR相关的疾病、疾病或症状中利用LXR调节剂的方法。本文还描述了含有这类化合物的药物组合物。
• An Optimised Small-Molecule Stabiliser of the 14-3-3-PMA2 Protein-Protein Interaction
  作者：Anja Richter、Rolf Rose、Christian Hedberg、Herbert Waldmann、Christian Ottmann

  DOI：10.1002/chem.201103761

  日期：2012.5.21

  Modulation of protein–protein interactions (PPIs) is a highly demanding, but also a very promising approach in chemical biology and targeted drug discovery. In contrast to inhibiting PPIs with small, chemically tractable molecules, stabilisation of these interactions can only be achieved with complex natural products, like rapamycin, FK506, taxol, forskolin, brefeldin and fusicoccin. Fusicoccin stabilises

  蛋白质间相互作用（PPI）的调节在化学生物学和靶向药物发现中是非常需要的，但也是非常有前途的方法。与使用化学上易处理的小分子抑制PPI相比，只有通过复杂的天然产物（如雷帕霉素，FK506，紫杉醇，福司可林，布雷菲德丁和富西花青素）才能实现这些相互作用的稳定化。Fusicoccin可稳定植物H + -ATPase PMA2和14-3-3蛋白的活化复合物。最近，我们已经表明，fusicoccin的稳定作用可以通过三取代的吡咯啉酮（pyrrolidone1，来模拟1）。在这里，我们报告1的衍生物的合成，功能活性和晶体结构可以稳定14-3-3-PMA2复合物。通过有限的化合物收集，可以确定对于活性增强而言很重要的三个修饰：1）吡咯烷酮支架向吡唑的转化； 2）将四唑部分引入与PMA2接触的苯环，以及3）添加溴与仅与14-3-3蛋白接触的苯环相连。1的吡唑衍生物与14-3-3和PMA2形成复合物的晶体
• Trisubstituted Pyrrolinones as Small-Molecule Inhibitors Disrupting the Protein–RNA Interaction of LIN28 and <i>Let-7</i>
  作者：Lydia Borgelt、Fu Li、Pascal Hommen、Philipp Lampe、Jimin Hwang、Georg L. Goebel、Sonja Sievers、Peng Wu

  DOI：10.1021/acsmedchemlett.0c00546

  日期：2021.6.10

  protein–RNA interaction (PRI) using small molecules is a promising strategy to develop therapeutics. LIN28 is an RNA-binding protein that blocks the maturation of the tumor suppressor let-7 microRNAs. Herein, we performed a fluorescence polarization-based screening and identified trisubstituted pyrrolinones as small-molecule inhibitors disrupting the LIN28–let-7 interaction. The most potent compound C902

  使用小分子调节蛋白质-RNA 相互作用 (PRI) 是开发治疗方法的一种有前景的策略。 LIN28 是一种 RNA 结合蛋白，可阻止抑癌基因let-7 microRNA 的成熟。在此，我们进行了基于荧光偏振的筛选，并鉴定出三取代吡咯啉酮作为破坏 LIN28 -let-7相互作用的小分子抑制剂。最有效的化合物 C902 在 EMSA 验证测定中显示出剂量依赖性抑制作用，增强了 LIN28 冷休克结构域的热稳定性，并增加了 JAR 细胞中成熟let-7 的水平。结构-活性关系研究揭示了有助于 PRI 抑制或蛋白质-蛋白质相互作用 (PPI) 稳定的关键结构特征。本研究中鉴定的吡咯啉酮不仅代表了一类新的 LIN28 结合分子，使有限的可用 LIN28 抑制剂多样化，而且代表了显示取代基依赖性 PRI 抑制和 PPI 激活活性的小分子的第一个例子。
• [EN] AZAINDAZOLES<br/>[FR] AZAINDAZOLES
  申请人：GLAX0SMITHKLINE LLC

  公开号：WO2013039988A1

  公开（公告）日：2013-03-21

  Herein are disclosed azaindazoles of formula (I), (I), where the various groups are defined herein, and which are useful for treating cancer.

  这里公开了公式(I)、(I)的氮杂吲唑，其中各团簇在本发明中定义，并且用于治疗癌症。
• [EN] LIVER X RECEPTOR (LXR) MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR HÉPATIQUE X (LXR)
  申请人：ALEXAR THERAPEUTICS INC

  公开号：WO2015035027A1

  公开（公告）日：2015-03-12

  Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of dermal diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

  本文描述了肝X受体（LXR）调节剂以及在治疗皮肤疾病、紊乱或状况中利用LXR调节剂的方法。本文还描述了含有这类化合物的药物组合物。